Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada

Abstract

BC patients in Ontario who did not complete adjuvant trastuzumab had a statistically significantly higher risk of BC relapse and death and low incidence of cardiac death. These findings support 1 year of adjuvant trastuzumab in early-stage BC.